Phase I-II study of biweekly paclitaxel administration with fixed-dose-rate cisplatin in advanced gastric cancer

Gastric Cancer

Volumn 9, Issue 1, 2006, Pages 36-43

  Yamaguchi, Kensei ^a   Shimamura, Tomotaka ^a   Komatsu, Yoshito ^b   Takagane, Akinori ^c   Yoshioka, Takashi ^d   Saitoh, Soh ^e   Munakata, Masaki ^f   Sakata, Yu ^f   Sato, Tsukasa ^g   Arai, Tatsuhiro ^h   Saitoh, Hiroshi ⁱ  

^a SAITAMA CANCER CENTER   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^f Misawa Municipal Hospital   (Japan)

^g Yamagata Prefectural Kahoku Hospital   (Japan)

^h TOCHIGI CANCER CENTER   (Japan)

ⁱ Yamagata Prefectural Central Hospital   (Japan)

Author keywords

Cisplatin; Gastric cancer; Paclitaxel

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EVALUATION; FATIGUE; FEMALE; FEVER; HEARTBURN; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OTALGIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CARCINOMA; STOMATITIS; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTESTINAL NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 33645238080     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-005-0355-2     Document Type: Article

References (22)

1. JA Ajani J Fairweather P Dumas YZ Patt R Pazdur PF Mansfield 1998 Phase II study of Taxol in patients with advanced gastric carcinoma Cancer J Sci Am 4 269 74
2. A Ohtsu N Boku F Tamura K Muro Y Shimada K Saigenji 1998 An early phase II study of a 3-h infusion of paclitaxel for advanced gastric cancer Am J Clin Oncol 21 416 9
3. Y Yamada K Shirao A Ohtsu N Boku I Hyodo H Saitoh 2001 Phase II trial of paclitaxel by 3-h infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions Ann Oncol 12 1133 7
4. K Yamaguchi M Tada N Horikoshi T Otani H Takiuchi S Saitoh 2002 Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer Gastric Cancer 5 90 5
5. M Ychou C Astre P Rouanet JM Fabre B Saint-Aubert J Domergue 1996 A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer Eur J Cancer 32A 1933 7
6. AD Roth R Maibach G Martinelli N Fazio MS Aapro O Pagani 2000 Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO) Ann Oncol 11 301 6
7. N Boku A Ohtsu Y Shimada K Shirao S Seki H Saito 1999 Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer J Clin Oncol 17 319 23
8. TC Chou RJ Motzer Y Tong GJ Bosl 1994 Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design J Natl Cancer Inst 19 1517 24
9. E Reed EC Kohn G Sarosy M Dabholkar P Davis J Jacob 1995 Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results Semin Oncol 22 3 Suppl 6 90 6
10. FE de Jongh R de Wit J Verweij A Sparreboom MJ van den Bent G Stoter 2002 Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer Eur J Cancer 38 2005 13
11. MB Polee J Verweij PD Siersema HW Tilanus TA Splinter G Stoter 2002 Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer Eur J Cancer 38 1495 500
12. KA Gelmon SE O'Reilly AW Tolcher C Campbell C Bryce J Ragaz 1996 Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer J Clin Oncol 14 1185 91
13. T Kurata T Tamura T Shinkai Y Ohe H Kunitoh T Kodama 2001 Phase I and pharmacological study of paclitaxel given over h with cisplatin for advanced non-small cell lung cancer Jpn J Clin Oncol 31 93 9
14. A van der Gaast TC Kok L Kerkhofs PD Siersema HW Tilanus TA Splinter 1999 Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer Br J Cancer 80 1052 7
15. RJ Gralla D Osoba MG Kris P Kirkbride PJ Hesketh LW Chinnery 1999 Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology J Clin Oncol 17 2971 94
16. Japanese Research Society for Gastric Cancer 1995 Japanese classification of gastric carcinoma M Nishi Y Omori Y Miwa Part IV. Response assessment of chemotherapy for gastric carcinoma First English edition. Kanehara Syuppan Tokyo
17. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 16
18. P Rosenberg H Andersson K Boman M Ridderheim B Sorbe U Puistola 2002 Randomized trial of single agent paclitaxel given weekly versus every 3 weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum Acta Oncol 41 418 24
19. GV Kornek M Raderer B Schull W Fiebiger C Gedlicka A Lenauer 2002 Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer Br J Cancer 86 1858 63
20. H Ozer JO Armitage CL Bennett J Crawford GD Demetri PA Pizzo 2000 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel J Clin Oncol 18 3558 85
21. LB Saltz J Kanowitz NE Kemeny L Schaaf D Spriggs BA Staton 1996 Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors J Clin Oncol 14 2959 67
22. LB Saltz JV Cox C Blanke LS Rosen L Fehrenbacher MJ Moore 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 905 14